Ixekizumab Injection bulk supplier for pharma manufacturers

Ixekizumab Injection 80 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Pre-filled autoinjector, pre-filled syringe (subcutaneous)

Available Strengths: 80 mg/mL

Pack Sizes: 1, 2 or 3 pens or syringes

Reference Brands: Taltz (Eli Lilly)

Ixekizumab (Taltz, Eli Lilly) is an IL-17A blocking antibody for plaque psoriasis, psoriatic arthritis and axial spondyloarthritis, given as an 80 mg injection under the skin. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ixekizumab Injection? List it or send an offer →

Product Description:

Ixekizumab is a monoclonal antibody that neutralises interleukin-17A (IL-17A), one of the main messengers driving skin plaques and joint inflammation in psoriatic disease. It acts quickly, and many patients see clear skin improvement within the first few weeks.

It is approved for moderate to severe plaque psoriasis in adults and children, active psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. Adults with psoriasis start with 160 mg (two injections), then 80 mg every two weeks for 12 weeks and every four weeks after that. Injection-site reactions are common; inflammatory bowel disease can flare and needs watching.

Sourcing notes. Ixekizumab is patented and there is no biosimilar. It is shipped and stored refrigerated. Secukinumab, another IL-17A antibody, is also listed on PharmaTradz.

How Ixekizumab Injection is supplied today, and licensing ahead of patent expiry

Ixekizumab Injection is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Ixekizumab Injection, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Ixekizumab Injection supply →

Back to Listing